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Introduction
Gastric cancer (GC) is the second cause of cancer 
related death in the world and has a heterogenous 
geographic pattern of distribution (Vannella et al., 2012). 
Different factors have been proposed in the pathogenesis 
of GC including helicobacter pylori (HP) infection (Zheng 
et al., 2014), smoking (Zhong et al., 2012), diet (Lin et al., 
2014) and family history (Mansour-Ghanaei et al., 2012). 
GC may develop by progression from its precancerous 
condition, called gastric atrophy (GA) (Kikuchi et al., 
2011). Subjects with chronic GA are more susceptible 
to GC (Kikuchi et al., 2011; Vannella et al., 2012). So, 
diagnosis and treatment of this condition has a pivotal role 
in GC prevention. In addition, diagnosis and treatment of 
GC in early stages is very important in controlling this 
fatal disease, especially in high-risk areas. Endoscopic 
examination of the stomach is the method of choice for 
diagnosis GA and GC (Kikuchi et al., 2011; Rollan et al., 
2006). But, it is an expensive and invasive method and 
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Abstract
 Background: Gastric cancer (GC) is the second cause of cancer related death in the world. It may develop by 
progression from its precancerous condition, called gastric atrophy (GA) due to gastritis. The aim of this study 
was to evaluate the accuracy of serum levels of pepsinogens (Pg) and gastrin-17 (G17) as non-invasive methods 
to discriminate GA or GC (GA/GC) patients. Materials and Methods: Subjects referred to gastrointestinal 
clinics of Golestan province of Iran during 2010 and 2011 were invited to participate. Serum levels of PgI, 
PgII and G17 were measured using a GastroPanel kit. Based on the pathological examination of endoscopic 
biopsy samples, subjects were classified into four groups: normal, non-atrophic gastritis, GA, and GC. Receiver 
operating curve (ROC) analysis was used to determine cut-off values. Indices of validity were calculated for 
serum markers. Results: Study groups were normal individuals (n=74), non-atrophic gastritis (n=90), GA (n=31) 
and GC patients (n=30). The best cut-off points for PgI, PgI/II ratio, G17 and HP were 80 μg/L, 10, 6 pmol/L, 
and 20 EIU, respectively. PgI could differentiate GA/GC with high accuracy (AUC=0.83; 95%CI: 0.76-0.89). 
The accuracy of a combination of PgI and PgI/II ratio for detecting GA/GC was also relatively high (AUC=0.78; 
95%CI: 0.70-0.86). Conclusions: Our findings suggested PgI alone as well as a combination of PgI and PgI/II 
ratio are valid markers to differentiate GA/GC. Therefore, Pgs may be considered in conducting GC screening 
programs in high-risk areas.  
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may not be considered at population level. So, it has been 
proposed to find alternative non-invasive methods for 
early diagnosis or screening of these conditions. 
Using serum biomarkers has been considered as 
potential screening method in this regards (Kikuchi et 
al., 2011). Pepsinogen enzyme (Pg), secreted from the 
gastric mucosa, has been suggested as a good non-invasive 
marker for diagnosis of corpus atrophic gastritis (Iijima et 
al., 2009; Kikuchi et al., 2011). Pg is classified into two 
main classes including PgI, which is solely secreted by 
fundic gland and PgII, which is secreted by pyloric glands 
and proximal duodenal mucosa. 
Gastrin-17 (G17) is another possible biomarker for 
diagnosis GA. A negative relationship has been reported 
between serum level of G17 and the severity of gastritis 
especially in the antrum, because it is almost solely 
secreted by G-cells (Kikuchi et al., 2011). 
Decrease in PgI, the ratio of PgI/PII and G17 may 
reflect the presence of abnormalities in gastric mucosa 
including atrophic gastritis and GC (Watabe et al., 2005; 
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Oishi et al., 2006; Yanaoka et al., 2008; Kikuchi et al., 
2011). Therefore, it is proposed that a combination of Pg 
and G17 may be helpful for diagnosis of atrophic gastritis 
and GC and consequently may be considered to develop 
a GC screening program (Shiotani et al., 2005; Rollan et 
al., 2006; Cao et al., 2007).
Golestan province located in northeastern Iran has 
been known as a high risk area for upper gastrointestinal 
cancers (Roshandel et al., 2012). As other high-risk areas, 
controlling GC is an important health issue in this region. 
Finding a screening program for early diagnosis of GC 
and its precursor lesions may be considered as the most 
effective strategy for controlling this disease in Golestan 
province as well as other high-risk areas. This study was 
designed to evaluate the accuracy of serum levels of Pg 
and G17 as non-invasive screening methods for early 
diagnosis of GA and GC.
Materials and Methods
This cross-sectional study was done in Golestan 
province of Iran during 2010-2011. Individuals who 
referred to gastrointestinal clinics for endoscopic 
examination, were invited to participate in our study. The 
exclusion criteria included history of chemotherapy or 
gastric surgery, history of helicobacter pylori eradication, 
history of anti-coagulant therapy and serious systemic 
diseases including diabetes, liver cirrhosis, and chronic 
renal failure.
A demographic questionnaire was completed including 
socio-demographic data and medical history. After 
obtaining informed consent, a fasting blood sample of 10 
cc was taken. Serum was separated and frozen in -20°c 
until use. Serum levels of PgI, PgII, G17 and HP antibody 
were measured using GastroPanel kit, Biohit, Finland. 
Endoscopic examination was done by gastroenterologists 
and biopsies were taken. Pathological examinations of 
biopsy samples were done by an expert pathologist and 
the results were reported according to the updated Sydney 
system (Dixon et al., 1996). Based on the pathological 
examination, subjects were classified into four groups 
including normal, non-atrophic gastritis, GA, and GC. 
Data was entered into computer using SPSS-16 
software and analyzed by chi-square, t-test and One-way 
ANOVA. Receiver operating curve (ROC) analysis was 
used to determine the cut-offs for PgI, PgI/II ratio, G17 
and HP. Sensitivity and specificity of these markers to 
distinguish the above mentioned groups (non-atrophic 
gastritis, GA, and GC) were calculated. Positive predictive 
value (PPV), negative predictive value (NPV), area under 
curves (AUC) and the 95% confidence intervals (CI) 
were also calculated and presented. Finally, regarding the 
clinical importance of GA and GC, the data of subjects 
with the diagnosis of GA or GC was merged to generate 
a combined group called GA/GC. Indices of validity of 
serum markers to distinguish GA/GC were also calculated. 
P-values of less than 0.05 were considered significant.
This study was approved by the ethical committee of 
Golestan University of Medical Sciences.
Results 
Totally, 234 subjects were recruited. The mean (SE) 
of participants’ age was 48.5 (1.1) years. 115 (49.1%) of 
participants were male with mean (SD) age of 50.3 (1.6) 
and the remaining were female with mean (SD) age of 
46.8 (1.4) years (p=0.1). Study groups included normal 
individuals (n=74), non-atrophic gastritis (n=90), GA 
Table 1. Demographic Characteristics and Serum Levels of Pepsinogen, Gastrin-17 and Helicobacter (HP) 
Antibody in Study Groups
Gender Normal  Non-atrophic  Gastric  Gastric p value
 (n=74) gastritis (n=90) atrophy (n=31) cancer (n=39) 
Male, N (%) 38 (51.4) 49 (54.4) 17 (54.8) 15 (38.5) 0.38
Female, N (%) 36 (48.6) 41 (45.6) 14 (45.2) 24 (61.5) 
Age (years), mean±SE 44.27±1.9 45.88±1.5 51.52±2.5 60.23±2.5 <0.001
Pepsinogen I (μg/L), mean±SE 135.19±9.4 96.94±5.4 66.50±9.9 51.40±5.8 <0.001
Pepsinogen II (μg/L), mean±SE 18.00±2.1 16.16±1.2 13.85±1.7 17.01±2.8 0.59
Pepsinogen I/II ratio, mean±SE 12.49±1.5 7.70±0.5 6.03±1.2 4.73±0.7 <0.001
Gastrin 17( pmol/L), mean±SE 13.56±2.1 13.82±1.7 8.32±1.6 10.81±2.8 0.34
HP antibody (EIU), mean±SE 26.39±3.0 55.20±2.7 56.90±4.9 46.43±4.4 <0.001
Table 2. Indices of Validity for Serum Levels of Pepsinogen I (PgI), PgI/II Ratio and Gastrin-17 (G17) to 
Distinguish Non-Atrophic Gastritis, Gastric Atrophy and Gastric Cancer
 Sensitivity Specificity Area Under ROC curve
Non-atrophic gastritis PgI<80 µg/l 47.7 (37.7-58.2) 72.6 (62.4-82.8) 0.57 (0.43-0.70)
 PgI/II ratio<10 77.3 (68.5-86.0) 38.0 (26.7-49.3) 0.59 (0.45-0.72)
 G17<6 pmol/l 45.6 (35.3-55.8) 47.9 (36.5-59.4) 0.46 (0.33-0.60)
Atrophic gastritis PgI<80 µg/l 77.4 (62.7-92.1) 72.6 (62.4-82.8) 0.80 (0.71-0.89)
 PgI/II ratio<10 90.3 (79.9-1.0) 38.0 (26.7-49.3) 0.74 (0.65-0.84)
 G17<6 pmol/l 64.5 (47.7-81.4) 47.9 (36.5-59.4) 0.56 (0.45-0.66)
Gastric cancer PgI<80 µg/l 87.2 (76.7-97.7) 72.6 (62.4-82.8) 0.85 (0.78-0.92)
 PgI/II ratio<10 92.3 (83.9-1.0) 38.0 (26.7-49.3) 0.79 (0.70-0.87)
 G17<6 pmol/l 43.6 (28.0-59.2) 47.9 (36.5-59.4) 0.51 (0.40-0.62)
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(n=31) and GC (n=30). Table 1 shows the characteristics 
of the study groups. The age was significantly higher in GC 
and atrophic gastritis groups than other ones. No significant 
difference was found in the level of PgI between GC and 
GA groups (p-value=0.3). The differences in serum levels 
of PgI between other groups were statistically significant. 
The serum levels of PgI/II ratio and HP antibody were 
significantly higher and lower, respectively in normal 
subjects than other groups.
The best cut-off points for PgI, PgI/II ratio, G17 and 
HP were 80 μg/L, 10, 6 pmol/L, and 20 EIU, respectively. 
The proportion of HP positivity was significantly 
lower in normal subjects (41.9%) than those with GC 
(87.2%), GA (90.3%) and non-atrophic gastritis (91.1%) 
(p-value<0.001). Table 2 shows the sensitivity, specificity 
and AUC of PgI, PgI/II ratio and G17 to distinguish 
non-atrophic gastritis, GA and GC. Indices of validity 
for each of the above-mentioned markers as well as their 
combinations to discriminate GA/GC patients are shown 
in table 3.
Discussion
The aim of this study was to evaluate the accuracy of 
serum levels of Pg and G17 as non-invasive screening 
methods for GC. Regarding the clinical importance of 
GA and GC, we mainly focused on assessing indices of 
validity of these markers to distinguish GA/GC patients. 
The results of this study showed that PgI could 
differentiate GA/GC with a high accuracy (AUC=0.83). 
The accuracy of a combination of PgI and PgI/II ratio for 
detecting GA/GC was also relatively high (AUC=0.78).
High accuracy for Pgs was reported for discriminating 
GA or GC in a number of previous studies. The results 
of a study from Portugal showed a sensitivity of 67% 
and a specificity of 47% for Pg for early detection of GC 
(Lomba-Viana et al., 2012). Cao et al found a high AUC 
(0.88) for PgI in patients with GA (Cao et al., 2007). 
Nasrollahzadeh et al (2011) similarly reported relatively 
high accuracy (AUC=0.78) for PgI as well as for the 
combination of PgI and PgI/II ratio (AUC=0.79) for 
diagnosis GA. Shikata et al (2012) reported a sensitivity 
and specificity of 71.0% and 69.2% for a combination 
of PgI and PgI/II ratio to discriminate GC. Miki et al 
(2003) reported a sensitivity of 80% and a specificity of 
70% for the combination of PgI and PgI/II ratio to detect 
GC. According to the results of a study by kitahara et al 
(1999), the sensitivity and specificity of this combination 
to distinguish GC were 84.6% and 73.5%, respectively.   
Therefore, PgI as well as a combination of PgI and 
PgI/II ratio may be considered as valid biomarkers for 
discriminating GA/GC. Regarding the clinical importance 
of GA and GC, detection of these conditions is the main 
aim of conducting screening programs. Therefore, PgI 
alone or a combination of PgI and PgI/II ration may be 
used in gastric cancer screening programs especially 
in high-risk areas. This may result in detection of 
precancerous lesions or early gastric cancers and finally 
may improve patients’ quality of life.
According to our findings, the accuracy of PgI alone 
was higher than its combination with PgI/II ratio. But, 
considering the pathophysiology of GA (Miki et al., 1993; 
Miki et al., 1987), the combination of PgI and PgI/II ratio 
may reflect a more accurate picture of the mucosal status 
in the stomach. Therefore, these points should be taken 
into consideration for conducting gastric cancer screening 
program in our area as well as other similar population.  
Our results did not suggest G17 alone as well as its 
combinations with Pgs as good biomarker for diagnosis 
of GA/GC. We also found no significant difference in 
serum levels of G17 between study groups. Shafaghi et al 
(2013) reported a low AUC (59%) for G17 for detecting 
GA. Cao et al similarly reported no significant difference 
in the serum levels of G17 between patients with GA and 
normal subjects (Cao et al., 2007). But, the results of some 
previous studies showed relatively high accuracy for G17 
to differentiate GA or GC. Nasrollahzadeh et al (2011) 
reported an AUC of 0.77 for G17 to discriminate GA. 
Kikushi et al (2011) also suggested G17 as good biomarker 
for diagnosis GA. Regarding the role of G17 pathogenesis 
of GC (Copps et al., 2009), further studies are warranted 
to assess the validity of G17 to differentiate GA/GC.
According to our findings, pepsinogens and G17 were 
not enough valid to differentiate non-atrophic gastritis. 
Nasrollahzadeh et al (2011) similarly reported a relatively 
low validity for Pgs and G17 to distinguish non-atrophic 
gastritis. Non-atrophic gastritis is not a clinically important 
pathology. In other words, there is no further evaluation 
for subjects diagnosed as non-atrophic gastritis. Therefore, 
detecting non-atrophic gastritis may not be an important 
goal in GC screening programs.
We found a significant higher frequency of HP 
positivity in patients with GC, GA and non-atrophic 
gastritis. The association of HP infection with GC and 
GA has been known, previously (Adamu et al., 2011; 
Correa, 1992). Ghasemi-Kebria et al (2011) reported high 
Table 3. Indices of Validity for Serum Levels of Pepsinogen I (PgI), PgI/II Ratio and Gastrin-17 (G17) and their 
Combinations to Distinguish Gastric Atrophy or Gastric Cancer
 Sensitivity Specificity PPV NPV AUC
PgI<80 µg/l 82.9 (74.0-91.7) 72.6 (62.4-82.8) 74.4 81.5 0.83 (0.76-0.89)
PgI<80 µg/l AND PgI/II ratio<10 80.0 (70.6-89.4) 76.1 (66.1-86.0) 76.7 79.4 0.78 (0.70-0.86)
PgI/II ratio<10 91.4 (84.9-98.0) 38.0 (26.7-49.3) 59.3 81.8 0.76 (0.69-0.84)
G17<6 52.9 (41.2-64.6) 47.9 (36.5-59.4) 49.3 51.5 0.53 (0.43-0.62)
PgI<80 µg/l AND G17<6 pmol/l 42.9 (31.3-54.5) 83.3 (74.7-91.9) 71.4 60 0.63 (0.54-0.72)
PgI<80 µg/l OR G17<6 pmol/l 92.9 (86.8-98.9) 36.1 (25.0-47.2) 58.6 83.9 0.65 (0.55-0.74)
PgI/II ratio<10 AND G17<6 pmol/l 50.0 (38.3-61.7) 73.2 (62.9-83.5) 64.8 59.8 0.62 (0.52-0.71)
PgI/II ratio<10 OR G17<6 pmol/l 94.3 (88.8-99.7) 12.7 (4.9-20.4) 51.6 69.2 0.54 (0.44-0.63)
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prevalence of HP infection in our area. Therefore, it is 
recommended to consider HP infection for conducting GC 
controlling programs (e.g. screening) in Golestan province 
of Iran as well as other high-risk areas.
In conclusion, our results suggested PgI alone and a 
combination of PgI and PgI/II ratio as valid markers to 
differentiate GA/GC. Therefore, Pgs may be considered 
in conducting GC screening programs in high-risk areas. 
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